Chlamydia W5-W6

The Chlamydia Trachomatis W5-W6 Recombinant is a recombinant protein derived from the bacterium Escherichia coli (E. coli). This recombinant protein contains epitopes from the major outer membrane protein (MOMP) of Chlamydia trachomatis, specifically amino acids 252-398 .

The W5-W6 recombinant protein is produced using a 6xHis fusion at the C-terminus, which facilitates purification. The protein is purified using proprietary chromatographic techniques to achieve a purity level of over 90%, as determined by SDS-PAGE .

The protein is formulated in a buffer containing 20mM Tris-HCl (pH 7.2), 50% glycerol, and 1.5M urea. It is stable at 4°C for up to one week but should be stored below -18°C to prevent freeze-thaw cycles .

The Chlamydia Trachomatis W5-W6 Recombinant protein is used in various laboratory research applications, including ELISA, Western Blot (WB), and Flow-Through assays. It is immunoreactive with sera from individuals infected with Chlamydia trachomatis, making it a valuable tool for diagnostic and research purposes .

Research has identified novel recombinant vaccine antigens for immunization against genital Chlamydia trachomatis. These antigens, including the W5-W6 recombinant protein, have shown promise in eliciting human CD4+ T-cell responses and providing protection against Chlamydia trachomatis infection in animal models . The development of an effective subunit vaccine against Chlamydia trachomatis could significantly reduce the global burden of this infection.

In summary, the Chlamydia Trachomatis W5-W6 Recombinant protein is a crucial component in the study and diagnosis of Chlamydia trachomatis infections. Its high purity, stability, and immunoreactivity make it an essential tool for researchers and clinicians working towards better understanding and combating this prevalent infection.